Merck's (MRK) PD-1 inhibitor, Pembrolizumab, completes a single-patient clinical trial for rare ovarian small cell carcinoma consolidation therapy.
Study Overview and Completion of Single-Patient Trial
A clinical trial (NCT05368207) of Merck's (MRK) PD-1 immune checkpoint inhibitor, Pembrolizumab (brand name: Keytruda), led by the Princess Margaret Cancer Centre under the University Health Network in Toronto, Canada, has been finalized. This study was a single-patient trial conducted on a patient with ovarian small cell carcinoma (SCCOHT) accompanied by hypercalcemia, exploring the new potential of the drug. SCCOHT is an extremely rare and aggressive disease, accounting for less than 0.1% of all ovarian cancers, and lacks established standard treatments, highlighting the importance of this clinical trial.
Clinical Design and Monitoring Method
This trial focused on evaluating the efficacy of Pembrolizumab as a consolidation therapy, administered after initial treatment to prevent cancer recurrence and eliminate residual cancer cells. The patient received a total of six cycles (6 administrations) of 200mg of Pembrolizumab intravenously every six weeks, and progression-free survival (PFS) over two years was monitored as the primary endpoint. CA-125 levels were checked every six weeks for tumor biomarker analysis, and circulating tumor DNA (ctDNA) analysis was conducted in parallel to observe minimal residual disease (MRD), allowing for comprehensive tracking of treatment response.
Paradigm Shift in Treatment and Mechanistic Significance
Ovarian small cell carcinoma (SCCOHT) primarily occurs in young women in their 20s and is characterized by the loss of function of the SMARCA4 gene, resulting in only temporary efficacy of cytotoxic chemotherapy. In this context, consolidation therapy with immune checkpoint inhibitors activates immune cells, particularly T cells, to induce the immune system to continuously monitor the tumor, potentially leading to a breakthrough in long-term survival. Although this is a single-patient trial, the completion data can serve as a turning point in introducing a new therapeutic paradigm of immune oncology in the underserved area of rare diseases with no standard treatments.
Market Prospects and Keytruda's Exclusive Rights
With the global ovarian cancer treatment market projected to reach approximately $4.09 billion to $4.83 billion in 2025, the rare cancer segment has high unmet medical needs and significant potential for exclusivity. Currently, in addition to existing platinum-based chemotherapy, targeted therapies such as EZH2 inhibitors and CDK4/6 inhibitors are being developed as competing pipelines, but their efficacy is limited. If Keytruda, Merck's flagship product with annual sales of $31.7 billion, accumulates efficacy data in this area, it is expected to maximize the market-leading effect by pursuing orphan drug designation.
In 2025, Merck's (MRK) Keytruda achieved global sales of $31.7 billion, and in preparation for patent expiration, it is expanding indications. The completion of this single-patient trial for ovarian small cell carcinoma (SCCOHT) represents a milestone in establishing a foothold in the unexplored market of rare cancer consolidation therapy. In the ovarian cancer market, estimated at $4.09 billion to $4.83 billion, SCCOHT patients are extremely rare and lack adequate standard treatments. Demonstrating superior progression-free survival (PFS) compared to platinum-based chemotherapy could lead to orphan drug designation and market exclusivity. From the perspective of academia and researchers, the study's value lies in overcoming the limitations of existing treatments such as cisplatin/etoposide by introducing immune checkpoint inhibitors and ctDNA-based minimal residual disease (MRD) tracking models, thereby enhancing clinical trial design. In the medium to long term, it is expected to provide an academic basis for expanding to large-scale basket trials or combination therapies based on single-patient data, allowing it to gain a competitive edge over competing pipelines such as EZH2 and CDK4/6 inhibitors in terms of market share.
Source: ClinicalTrials.gov (api_ct)